Loading
Life sciences · Journal article
Obesity Pillars · September 19, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background. Incretin-based therapies are highly effective for weight reduction, but changes in lean mass during treatment remain a clinical concern. This study evaluated changes in fat mass and lean mass in individuals receiving structured exercise and nutritional support during incretin-based therapies.Methods. In this single-center retrospective observational chart-review study, 11 adults who underwent 9-12 months of incretin-based therapy and were offered a program providing supervised exercise and individualized nutritional support were analyzed. No control group was included. Treatments included glucagon-like peptide-1 (GLP-1) receptor agonists and glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor co-agonists. Body composition was assessed using dual-energy X-ray absorptiometry (DXA). Data were assessed for parametric assumptions, and pre- and post-intervention comparisons were performed using paired-samples t tests.Results. Significant reductions were observed in body weight (mean change: -4.99 kg [95% CI: -7.65 to -2.34]; p = 0.002) and fat mass (-4.37 kg [95% CI: 6.36 to -2.39]; p < 0.001), corresponding to a mean total weight reduction of 4.71% and a mean fat mass reduction of 11.06%, respectively. Lean mass did not change significantly (-0.62 kg [95% CI: 2.20 - 0.95]; p = 0.397). At the aggregate cohort-level, weight reduction composition analysis indicated that 87.58% of total weight reduction was attributable to fat mass, and 12.42% to lean mass.Conclusion. Incretin-based therapy delivered within a structured exercise and nutritional support program was associated with fat-dominant weight reduction without a statistically significant change in lean mass. These findings are hypothesis-generating and warrant confirmation in adequately powered prospective controlled studies.